Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Physalis alkekengi polysaccharide is a natural substance extracted from the Chinese lantern plant (*Physalis alkekengi L.*), which is under investigation for its potential therapeutic effects in type 2 diabetes mellitus (T2DM). Preclinical studies in T2DM mouse models suggest it exerts hypoglycemic effects by reducing fasting blood glucose, improving glucose tolerance, and decreasing insulin resistance. Its proposed mechanisms of action include the inhibition of α-glucosidase, regulation of blood lipid levels (reducing total cholesterol and triglycerides), and enhancement of the antioxidant capacity in the liver and pancreas. Furthermore, research indicates it may modulate gut health by increasing the expression of G protein-coupled receptor 43 (GPR43) and glucagon-like peptide-1 (GLP-1) in the colon and pancreas.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on physalis alkekengi polysaccharide.